Empagliflozin (Jardiance ) Trade Names: Jardiance Drug Class: Anti-diabetic drug, Hypoglycemic, SGLT-2 inhibitor, Gliflozin Mechanism of Action: Hypoglycemic : Inhibits the Na-glucose co-transporter 2 (SGLT-2) in the kidney to reduce glucose reabsorption, resulting in increased urinary glucose excretion, and lower plasma glucose
Suspected adverse effects should be reported via the MHRA Yellow Card Scheme
Benefits may appear within a few weeks of consistent intake, depending on diet quality, lifestyle, metabolism, and overall health condition
It has been shown to have a variety of healing properties, including promoting the growth of new blood vessels, reducing inflammation, and accelerating wound healing
10.1136/gut.2004.059741 48 StillingR